KKR: EU approves joint acquisition of Immedica Pharma
(CercleFinance.com) - The European Commission has approved the acquisition of joint control of Immedica Pharma by Impilo and KKR.
The transaction mainly concerns the marketing of drugs for rare diseases and specialized care products.
The Commission concluded that the notified transaction would not raise competition concerns, given the limited market positions of the companies resulting from the proposed transaction.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The transaction mainly concerns the marketing of drugs for rare diseases and specialized care products.
The Commission concluded that the notified transaction would not raise competition concerns, given the limited market positions of the companies resulting from the proposed transaction.
Copyright (c) 2024 CercleFinance.com. All rights reserved.